<DOC>
	<DOCNO>NCT00876174</DOCNO>
	<brief_summary>The objective pilot project investigate prognostic criterion sensitivity Chronic Hepatitis C ( CHC ) Genotype 1 , patient IFNa treatment . Signal transduction peripheral blood mononuclear cell ( PBMC ) control group compare CHC patient . For study , 20 patient Hepatitis C virus ( HCV ) infection undergo standard antiviral therapy 10 healthy donor ( significant others HCV subject ) enrol . Signal transduction study peripheral blood CHC subject treatment , 1 3 month treatment , 4-6 month follow completion treatment .</brief_summary>
	<brief_title>Effects Genotypes Interferon Signaling Chronic Hepatitis C</brief_title>
	<detailed_description>In addition , mechanism non-responsiveness HCV patient IFNa study . For purpose , formation complex STAT1 negative regulator , PIAS1 ( immunoprecipitation , Western blot ) examine . In compare subject standard therapy v addition betaine , ( separate study ) assess whether formation STAT1-PIAS1 complex due impaired methylation STAT1 arginine residue may come addition betaine .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>1 . 19 year age old , either gender . 2 . History chronic hepatitis C document HCVRNA . 3. . Documented genotype 1 . 4 . Subject prescribed antiviral therapy 5 . Able give inform consent . Controls : 1 . Greater 19 year age . 2 . Subject report good general health . 3 . Subject deny chronic hepatitis C infection . 4 . Able give inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>Chronic hepatitis C</keyword>
	<keyword>Genotype 1</keyword>
</DOC>